Vivactil

Depression

Treatment

1 FDA approval

20 Active Studies for Vivactil

What is Vivactil

Protriptyline

The Generic name of this drug

Treatment Summary

Protriptyline hydrochloride is an antidepressant medication used to treat depression. It belongs to the tricyclic antidepressant (TCA) class of drugs which increase serotonin and norepinephrine levels in the brain to help alleviate symptoms of depression. It can also cause sedation in non-depressed individuals and has side effects such as blurred vision, dry mouth, constipation, and urinary retention.

Vivactil

is the brand name

image of different drug pills on a surface

Vivactil Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Vivactil

Protriptyline

2000

15

Approved as Treatment by the FDA

Protriptyline, commonly known as Vivactil, is approved by the FDA for 1 uses including Depression .

Depression

Helps manage Depression

Effectiveness

How Vivactil Affects Patients

Protriptyline is a type of antidepressant that works by increasing the levels of norepinephrine and serotonin in the brain. It usually takes two weeks to start seeing results. This drug may also make it easier to regulate emotions, reduce pain, and prevent migraines. The specific way it works to reduce pain is not known, but it is believed that it affects the body’s natural opioid system.

How Vivactil works in the body

Protriptyline helps the body keep more of the naturally occurring chemicals norepinephrine and serotonin in the brain, which can help relieve symptoms of depression.

When to interrupt dosage

The advised dosage of Vivactil is contingent upon the determined condition. The amount also fluctuates as per the approach of delivery listed in the table below.

Condition

Dosage

Administration

Depression

5.0 mg, , 10.0 mg

, Tablet, film coated, Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Vivactil Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Vivactil.

Common Vivactil Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Protriptyline may increase the vasopressor activities of 4-Methoxyamphetamine.

Azelastine

Major

Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Bromocriptine

Major

Protriptyline may increase the vasopressor activities of Bromocriptine.

Cirazoline

Major

Protriptyline may increase the vasopressor activities of Cirazoline.

Desvenlafaxine

Major

The risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.

Vivactil Toxicity & Overdose Risk

Possible side effects of taking the drug include anxiety, blood disorders, confusion, decreased sex drive, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, irregular heartbeat, rash, seizures, sensitivity to sunlight, digestive issues, drowsiness, low blood pressure when standing, blurred vision, dry mouth, constipation, difficulty urinating, worsened memory and delirium, and worsening of bipolar depression. Withdrawal symptoms can include digestive problems, anxiety, and difficulty sleeping.

image of a doctor in a lab doing drug, clinical research

Vivactil Novel Uses: Which Conditions Have a Clinical Trial Featuring Vivactil?

602 active trials are presently being conducted to assess the efficacy of Vivactil in alleviating symptoms of Depression.

Condition

Clinical Trials

Trial Phases

Depression

304 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Vivactil Reviews: What are patients saying about Vivactil?

5

Patient Review

1/20/2009

Vivactil for Generalized Attack of Muscular Weakness

I was originally prescribed this medication for headaches when I was 16. Unfortunately, it caused me to become more depressed so they added another antidepressant. I took the combination of drugs for three years but my condition continued to worsen. In my opinion, antidepressants should be closely monitored by parents of teenagers.

4

Patient Review

3/24/2011

Vivactil for Generalized Attack of Muscular Weakness

I was prescribed this as an abortive for migraines. I have been on this and several other medications for 4 months. I do not think this medication is working for me at all. I am supposed to take up to 3 15mg as needed but it never takes the migraine away.

3

Patient Review

11/5/2007

Vivactil for Depression

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vivactil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is protriptyline?

"Protriptyline is a tricyclic antidepressant that works by increasing the amounts of certain natural substances in the brain that help maintain mental balance."

Answered by AI

What is Vivactil used for?

"This medication is used to treat mental and mood problems. Some of the benefits include improved mood, feelings of well-being, and increased energy levels. It is classified as a tricyclic antidepressant."

Answered by AI

Does protriptyline have side effects?

"The following side effects may occur: drowsiness, dizziness, dry mouth, blurred vision, constipation, weight gain, or trouble urinating. If you experience any of these side effects, tell your doctor or pharmacist. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position."

Answered by AI

What is the generic name for Vivactil?

"Vivactil is an antidepressant that is used to treat symptoms of depression. Vivactil is a tricyclic antidepressant, which is a type of antidepressant that is used to treat symptoms of depression."

Answered by AI

Clinical Trials for Vivactil

Image of University of California, Los Angeles in Los Angeles, United States.

Digital Therapy for Postpartum Depression

18+
Female
Los Angeles, CA

The purpose of this study is to determine if the addition of digital sensing data collected from phones and watches during the early stages of perinatal depression (PND) treatment can better predict treatment outcomes than using self-reported symptoms alone.STAND for PND: The UCLA Depression Grand Challenge (DGC) has previously developed a technology-assisted, scalable therapy system called STAND (Screening and Treatment for ANxiety and Depression) for perinatal depression (PND) and has demonstrated in an initial randomized clinical trial that this treatment intervention to be as effective as psychiatrist delivered care for PND. In this study, the investigators will administer STAND for PND for up to 12 weeks as part of study participation. There will be no comparison between our treatment intervention and a treatment as usual condition, as this is not a trial of efficacy. In the STAND for PND treatment model, women with moderate symptoms will be routed to coach-guided, digital cognitive behavioral therapy (CBT) tailored to PND, which has been demonstrated to be an effective treatment approach for PND. Women with severe depression or suicidality will be routed to clinician delivered CBT, with pharmacotherapy as needed, with both CBT and pharmacotherapy demonstrated to be effective treatment approaches for PND. Symptoms will be regularly monitored throughout the intervention period. Digital Sensing in Depression: The DGC also has substantial experience in large-scale longitudinal digital sensing studies, and experience identifying associations between self-report or clinical ratings of depressive symptoms and digital sensing features, including in pregnant and postpartum women. Digital Sensing in a STAND for PND study: In our previous STAND for PND study, the investigators did not include digital sensing. In this next phase of our research program, the investigators will collect digital sensing data from phones and watches during the first four weeks of study participation. The investigators will enroll up to 250 women during their last trimester or who are in the postpartum period to participate in the 12-week study, which includes treatment provided through the STAND for PND program of care and during which the investigators will obtain 4-weeks of digital sensing data.The investigators will be testing whether behaviors measures through digital sensing (i.e., digital features) in combination with self-reported depression symptoms will better predict treatment outcomes than the self-reported depression symptoms alone. The investigators are testing the hypothesis that prospective longitudinal assessments using digital devices will enhance our ability to predict outcomes of STAND-PND.This project is part of a larger program of research that aims to improve clinical decision-making for PND by establishing a clinical care model for PND that fully integrates digital sensing with digital therapy. An additional objective of this program of research is to target low-income mothers from populations that have had limited access to mental healthcare, given that this population is particularly vulnerable to the impact of PND.

Waitlist Available
Has No Placebo

University of California, Los Angeles

Nelson Freimer, MD

Image of Imperial Valley College in Imperial, United States.

Cognitive Behavioral Therapy for Mental Health

18+
All Sexes
Imperial, CA

The goal of this study is to understand why certain treatments help people reduce repetitive negative thinking (RNT), which is common in many mental health problems. We want to: 1. Figure out what actually causes repetitive negative thinking to decrease when people use cognitive-behavioral therapy (CBT). 2. Find out which parts of RNT-focused CBT are the most important - the parts that truly make a difference in reducing RNT. The main result we will look at is how much a person's repetitive negative thought patterns change from the start of the study to the end of treatment (16 weeks). We will measure this using the Perseverative Thinking Questionnaire at baseline and week 16.

Waitlist Available
Has No Placebo

Imperial Valley College

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Have you considered Vivactil clinical trials?

We made a collection of clinical trials featuring Vivactil, we think they might fit your search criteria.
Go to Trials
Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

Cognitive Training + tDCS for Depression

18+
All Sexes
Nashville, TN

The goal of this clinical trial is to learn if a combination of non-drug treatments works to benefit memory, thinking, and brain functioning in older individuals with recurrent depression. The non-drug approaches the investigators are studying include transcranial direct current stimulation (tDCS) and computerized cognitive training. tDCS uses small currents of electricity on the forehead to potentially stimulate your brain's ability to process and learn. Computerized cognitive training uses tablet games to improve memory and thinking. In this study, two different cognitive training programs are being investigated, both of which are stimulating and designed to engage brain activity. One that is believed to be a specific treatment for depression, while the other provides extra stimulation for the brain that is non-specific. Two different tDCS parameters - active stimulation and sham (or placebo) stimulation - are also being investigated. Participants will be randomized to one of three study groups: 1. Depression cognitive training treatment with active brain stimulation 2. Depression cognitive training treatment with sham brain stimulation 3. Non-specific cognitive training treatment with sham brain stimulation The main questions this clinical trial aims to answer are: * Does "depression cognitive training treatment with active brain stimulation" benefit thinking and memory more so than the other treatments? * Does "depression cognitive training treatment with active brain stimulation" benefit brain functioning more so than the other treatments? Participants will: * Complete several baseline and post-intervention visits at the research center for checkups and tests over the course of 3-4 months. * Visit the research center daily for 4 weeks to complete their assigned treatment.

Waitlist Available
Has No Placebo

Vanderbilt University Medical Center

Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Have you considered Vivactil clinical trials?

We made a collection of clinical trials featuring Vivactil, we think they might fit your search criteria.
Go to Trials
Image of CVT in Centennial, United States.

Treatment for Depression

18 - 70
All Sexes
Centennial, CO

The goal of this hybrid implementation-effectiveness study is to learn about the effectiveness and appropriateness of "Trauma-Informed and Culturally-Responsive Integrated Massage Therapy" (TCI-Massage) for torture and war trauma survivors. The study aims are: • Examine the uptake of TCI-Massage within CVT by assessing key implementation science outcomes of acceptability and appropriateness among refugees and asylum seekers from diverse cultural backgrounds. • Examine the integration of massage therapy into the current psychosocial care model used at CVT. • Examine the effectiveness of TCI-Massage for torture and war trauma survivors to reduce distress (mental health symptoms, chronic pain, and HRV) and improve coping (interoceptive awareness and social functioning). Treatment group participants will participate in psychosocial care services + TCI-Massage, which the control group will only participate in psychosocial care services

Waitlist Available
Has No Placebo

CVT

Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Have you considered Vivactil clinical trials?

We made a collection of clinical trials featuring Vivactil, we think they might fit your search criteria.
Go to Trials